We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

By LabMedica International staff writers
Posted on 16 Apr 2024
Print article
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective of whether mutations are present. Researchers have identified various signature patterns of gene activation in SCLC, and these subtypes dictate how the cancer responds to treatments and its specific vulnerabilities. There is a significant need for blood-based tests that can determine SCLC subtypes, track disease progression, recognize transformations into other types of lung cancer, and identify potential treatment targets, especially when standard biopsies are not feasible. Scientists have now made progress towards a liquid biopsy capable of distinguishing between multiple SCLC subtypes from blood samples.

New research at Fred Hutch Cancer Center (Seattle, WA, USA) has revealed that big-picture patterns of DNA packaging, gene activation, and mutations may provide the information required to develop a blood-based biopsy for SCLC patients. The team demonstrated that they could use cell-free tumor DNA from blood samples to differentiate between SCLC and non-small cell lung cancer (NSCLC), as well as among different subtypes of SCLC. They employed sophisticated computational techniques to analyze patterns in the activation status of hundreds to thousands of genes, revealing the gene activity and regulation within the tumors. Unlike most clinical circulating tumor DNA tests that focus on changes to DNA sequences, this new assay is designed to reveal gene activity and regulation status in tumors using a snippet of cell-free DNA.

SCLC typically responds well initially to chemotherapy, but recurrence is common. Recently, the integration of immune checkpoint inhibitors with standard treatments has improved survival rates, though these are not cures. The distinct gene expression patterns of SCLC and NSCLC can have significant implications for treatment effectiveness. For instance, certain SCLC subtypes show enhanced responsiveness to immunotherapy, which is not universally effective across all patients. Moreover, it is possible for tumors initially diagnosed as NSCLC to evolve into SCLC to evade treatment. This new assay could empower oncologists to customize SCLC treatments as more targeted therapeutic options become available, monitor for disease recurrence, and detect shifts from NSCLC to SCLC, thereby positively impacting both prognosis and treatment approaches.

“Our approach demonstrates that a full-featured circulating tumor DNA assay has the potential to classify clinical subtypes driven by transcriptional programs,” said Fred Hutch computational biologist Gavin Ha, PhD. “This assay expands the boundaries for potentially using circulating tumor DNA to improve treatment selection and cancer management.”

Related Links:
Fred Hutch Cancer Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Plasma Control
Plasma Control Level 1

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.